- Privately-held A2 Biotherapeutics has entered into an agreement with Merck (MRK +1.1%), in which A2 will continue research and preclinical development of its undisclosed Tmod cell therapy candidate (its third candidate therapy), with the parties to co-fund A2's clinical development and allogeneic manufacturing activities through Phase 1.
- Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1.
- A2's Tmod engineered T cells uniquely combine a potent activating mechanism to kill tumor cells with a blocking mechanism that protects normal cells from harm by exploiting the loss of genetic material in tumors.
Under the agreement A2 will receive an upfront payment, and will be eligible for opt-in and milestone payments, plus royalties on sales of any approved product. A2 will also receive from Merck an equity investment and reimbursement of certain expenses. Merck has the option to designate a new Tmod program with increased economic terms.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.